Is tM6SF2 E167K variant associated with severe steatosis in chronic hepatitis C , regardless of PNPLA3 polymorphism?
This is the first demonstration that TM6SF2 E167K variant is an independent predictor of liver steatosis in chronic hepatitis C.
In patients>or=65 yr, CHC is more severe and presents with lower ALT than in younger patients. Treatment is effective. Biochemical markers seem particularly useful as a noninvasive alternative to liver biopsy in this population.